Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Fujifilm, Kyowa Kirin to Set Up Joint Venture for Biosimilars in 2012
November 17, 2011
- Takeda Initiates PII Trials of Inactivated Poliovirus, Combined 4-valent Vaccine TAD-361S in Japan
November 17, 2011
- Synix to Establish Oncology Market Research Division in December
November 17, 2011
- Zeria Aims at 50% Domestic Market Share for UC Treatment Asacol in FY2011
November 17, 2011
- High Court’s Ruling in Iressa Appeal “Extremely Fair and Reasonable”: Attorney for AZ
November 16, 2011
- Survey Finds 33% Pharmacists and Pharmacy Students Know “Established Drugs”
November 16, 2011
- Anticancer Drug SyB L-0501 Starts PII Trial for Refractory, Relapsed Multiple Myeloma (MM): SymBio
November 16, 2011
- MEDINET Initiates Clinical Study of DC Vaccine
November 16, 2011
- Japan’s Jul-Sep 2011 Ethical Drug Market Grows 7.7%: IMS Japan
November 15, 2011
- Domestic Vaccine Market Showing Strong Growth
November 15, 2011
- Sawai President to Increase “Hospital MRs” to 100
November 15, 2011
- CMIC to Develop Orphan Drugs With Partners, Funds: Chairman Nakamura
November 15, 2011
- Bayer Yakuhin Modifies Storage Conditions for Kogenate FS for Home Use
November 15, 2011
- EPS: Solid Growth in Sales, Profits Driven by SMO, CSO Businesses
November 15, 2011
- Otsuka Draws Up Strategy in Anticipation of Abilify Patent Expiration
November 14, 2011
- Otsuka Forms Alliance with Lundbeck in CNS Field
November 14, 2011
- Astellas Completes Recombinant Flu Vaccine Inoculation of Subjects of PII Trials
November 14, 2011
- SymBio Initiates Domestic PII Clinical Trials of Bendamustine for Add’l Indications
November 14, 2011
- Pharmaceutical Sales Down 2.2 % due to Decrease in Sales of Elplat: Yakult
November 14, 2011
- Antibody Drugs to Support Kyowa Kirin’s Growth Over Next 10 Years: Dr Oshima
November 14, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…